Cell therapies for Parkinson’s disease have been under development for a very long time indeed, decades at this point. The condition is characterized by aggregation of α-synuclein and loss of the small but critical population of dopamine-generating neurons in the brain. The latter is the proximate of cause of the loss of motor control and depression observed in patients. These cells are particularly sensitive to the combination of toxic α-synuclein biochemistry, <a href="https://www.fightaging.org/archives/2017/12/reviewing-the-mitochondrial-contribution-…
Slow Progress Towards Autologous Cell Therapies for Parkinson's Disease
Cell therapies for Parkinson’s disease have been under development for a very long time indeed, decades at this point. The condition is characterized by aggregation of α-synuclein and loss of the small but critical population of dopamine-generating neurons in the brain. The latter is the proximate of cause of the loss of motor control and depression observed in patients. These cells are particularly sensitive to the combination of toxic α-synuclein biochemistry, <a href="https://www.fightaging.org/archives/2017/12/reviewing-the-mitochondrial-contribution-…